Reuters Market Eye - Credit Suisse upgrades Dr. Reddy's Laboratories(REDY.NS) to 'outperform' from 'neutral' and raises its target price to 2,150 rupees from 1,900 rupees, citing expectations for a strong pick up in U.S. sales in the coming quarters.
Credit Suisse also notes the market share for Dr. Reddy's Metoprolol drug, used for hypertension, is increasing.
Dr. Reddy's also expects upcoming approval of two limited competition products in the United States, Credit Suisse says after meeting with the drug maker's management.
Dr. Reddy's also expects fiscal 2015 growth in the United States to be stronger than fiscal 2014 due to some "significant" launches.
Trending On Reuters
Earthquake Strikes Nepal
Nepal urged countries to send aid to help it cope with the aftermath of a devastating earthquake that killed nearly 1,400 people, a toll predicted to rise as rescuers used their hands to dig for survivors among the rubble on Sunday. Full Article | Nepal earthquake epicentre map
RBI chief Rajan calls for formal financing routes for farmers - report Full Article
India to host Afghan leader, seeks to regain ground lost to China, Pakistan Full Article